Aquentium Enters Multi-Billion Dollar Vapor Market with Nutritional e-Liquid
Canyon Lake, CA, March 11, 2015 --(PR.com)-- Aquentium, Inc. (OTC:AQNM) announced today that company is expanding into the multi-billion dollar vapor market. Aquentium's subsidiary, Immune BioPharma, Inc. has developed a nutritional e-liquid that is fortified with vitamins and minerals. The Immune BioPharma e-liquid is non-toxic and does not contain any nicotine or CBD.
"While the typical vaper is a former smoker, who first tried e-cigs and then quickly moved to tank-style systems and eventually mods, which offer a much stronger battery and a superior vaping experience, we believe our nutritional e-liquid will expand beyond the typical nicotine users as our product is 100% organic and fortified with vitamins and adaptogenic minerals," stated Aquentium CEO Mark Taggatz.
Aquentium and its subsidiary Immune BioPharma, Inc. do not promote or endorse the use of nicotine or cbd and will continue to develop stand alone e-liquids that promote health and wellness for people throughout the world.
The following press release is for informational use only and is not an offer to buy or sell securities. Certain statements in this news release may contain "forward- looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. There can be no assurance that such forward-looking statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
.
"While the typical vaper is a former smoker, who first tried e-cigs and then quickly moved to tank-style systems and eventually mods, which offer a much stronger battery and a superior vaping experience, we believe our nutritional e-liquid will expand beyond the typical nicotine users as our product is 100% organic and fortified with vitamins and adaptogenic minerals," stated Aquentium CEO Mark Taggatz.
Aquentium and its subsidiary Immune BioPharma, Inc. do not promote or endorse the use of nicotine or cbd and will continue to develop stand alone e-liquids that promote health and wellness for people throughout the world.
The following press release is for informational use only and is not an offer to buy or sell securities. Certain statements in this news release may contain "forward- looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. There can be no assurance that such forward-looking statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
.
Contact
Aquentium
Mark Taggatz
951-244-8208
www.aquentium.com
Contact
Mark Taggatz
951-244-8208
www.aquentium.com
Categories